Gene therapy for the regeneration of bone

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Gene transfer technologies offer the prospect of enhancing bone regeneration by delivering osteogenic gene products locally to osseous defects. In most cases the gene product will be a protein, which will be synthesized endogenously within and around the lesion in a sustained fashion. It will have undergone authentic post-translational processing and lack the alterations that occur when recombinant proteins are synthesized in bioreactors and stored. Several different ex vivo and in vivo gene delivery strategies have been developed for this purpose, using viral and non-viral vectors. Proof of principle has been established in small animal models using a variety of different transgenes, including those encoding morphogens, growth factors, angiogenic factors, and transcription factors. A small number of studies demonstrate efficacy in large animal models. Developing these promising findings into clinical trials will be a long process, constrained by economic, regulatory and practical considerations. Nevertheless, the overall climate for gene therapy is improving, permitting optimism that applications in bone regeneration will eventually become available.

Original languageEnglish (US)
Pages (from-to)599-604
Number of pages6
JournalInjury
Volume42
Issue number6
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Bone Regeneration
Genetic Therapy
Genes
Animal Models
Climatotherapy
Technology Transfer
Angiogenesis Inducing Agents
Bioreactors
Transgenes
Recombinant Proteins
Intercellular Signaling Peptides and Proteins
Transcription Factors
Economics
Clinical Trials
Proteins

Keywords

  • Adeno-associated virus
  • Adenovirus
  • Allograft revitalization
  • Animal model
  • Clinical trial
  • Gene activated matrix
  • Osteoblast
  • Osteoprogenitor cell
  • Vector

ASJC Scopus subject areas

  • Emergency Medicine
  • Orthopedics and Sports Medicine

Cite this

Gene therapy for the regeneration of bone. / Evans, Christopher H.

In: Injury, Vol. 42, No. 6, 06.2011, p. 599-604.

Research output: Contribution to journalArticle

Evans, Christopher H. / Gene therapy for the regeneration of bone. In: Injury. 2011 ; Vol. 42, No. 6. pp. 599-604.
@article{ce47a66175db46e4874139db53077b1d,
title = "Gene therapy for the regeneration of bone",
abstract = "Gene transfer technologies offer the prospect of enhancing bone regeneration by delivering osteogenic gene products locally to osseous defects. In most cases the gene product will be a protein, which will be synthesized endogenously within and around the lesion in a sustained fashion. It will have undergone authentic post-translational processing and lack the alterations that occur when recombinant proteins are synthesized in bioreactors and stored. Several different ex vivo and in vivo gene delivery strategies have been developed for this purpose, using viral and non-viral vectors. Proof of principle has been established in small animal models using a variety of different transgenes, including those encoding morphogens, growth factors, angiogenic factors, and transcription factors. A small number of studies demonstrate efficacy in large animal models. Developing these promising findings into clinical trials will be a long process, constrained by economic, regulatory and practical considerations. Nevertheless, the overall climate for gene therapy is improving, permitting optimism that applications in bone regeneration will eventually become available.",
keywords = "Adeno-associated virus, Adenovirus, Allograft revitalization, Animal model, Clinical trial, Gene activated matrix, Osteoblast, Osteoprogenitor cell, Vector",
author = "Evans, {Christopher H}",
year = "2011",
month = "6",
doi = "10.1016/j.injury.2011.03.032",
language = "English (US)",
volume = "42",
pages = "599--604",
journal = "Injury",
issn = "0020-1383",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Gene therapy for the regeneration of bone

AU - Evans, Christopher H

PY - 2011/6

Y1 - 2011/6

N2 - Gene transfer technologies offer the prospect of enhancing bone regeneration by delivering osteogenic gene products locally to osseous defects. In most cases the gene product will be a protein, which will be synthesized endogenously within and around the lesion in a sustained fashion. It will have undergone authentic post-translational processing and lack the alterations that occur when recombinant proteins are synthesized in bioreactors and stored. Several different ex vivo and in vivo gene delivery strategies have been developed for this purpose, using viral and non-viral vectors. Proof of principle has been established in small animal models using a variety of different transgenes, including those encoding morphogens, growth factors, angiogenic factors, and transcription factors. A small number of studies demonstrate efficacy in large animal models. Developing these promising findings into clinical trials will be a long process, constrained by economic, regulatory and practical considerations. Nevertheless, the overall climate for gene therapy is improving, permitting optimism that applications in bone regeneration will eventually become available.

AB - Gene transfer technologies offer the prospect of enhancing bone regeneration by delivering osteogenic gene products locally to osseous defects. In most cases the gene product will be a protein, which will be synthesized endogenously within and around the lesion in a sustained fashion. It will have undergone authentic post-translational processing and lack the alterations that occur when recombinant proteins are synthesized in bioreactors and stored. Several different ex vivo and in vivo gene delivery strategies have been developed for this purpose, using viral and non-viral vectors. Proof of principle has been established in small animal models using a variety of different transgenes, including those encoding morphogens, growth factors, angiogenic factors, and transcription factors. A small number of studies demonstrate efficacy in large animal models. Developing these promising findings into clinical trials will be a long process, constrained by economic, regulatory and practical considerations. Nevertheless, the overall climate for gene therapy is improving, permitting optimism that applications in bone regeneration will eventually become available.

KW - Adeno-associated virus

KW - Adenovirus

KW - Allograft revitalization

KW - Animal model

KW - Clinical trial

KW - Gene activated matrix

KW - Osteoblast

KW - Osteoprogenitor cell

KW - Vector

UR - http://www.scopus.com/inward/record.url?scp=79957797244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957797244&partnerID=8YFLogxK

U2 - 10.1016/j.injury.2011.03.032

DO - 10.1016/j.injury.2011.03.032

M3 - Article

C2 - 21489526

AN - SCOPUS:79957797244

VL - 42

SP - 599

EP - 604

JO - Injury

JF - Injury

SN - 0020-1383

IS - 6

ER -